NL1044087A - Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) - Google Patents
Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) Download PDFInfo
- Publication number
- NL1044087A NL1044087A NL1044087A NL1044087A NL1044087A NL 1044087 A NL1044087 A NL 1044087A NL 1044087 A NL1044087 A NL 1044087A NL 1044087 A NL1044087 A NL 1044087A NL 1044087 A NL1044087 A NL 1044087A
- Authority
- NL
- Netherlands
- Prior art keywords
- nmn
- vitamin
- effects
- resveratrol
- red ginseng
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Vitamin C (1) has proven antioxidant properties, while red ginseng (2) has been proven to improve immune function and healthy blood flow. In a preclinical and clinical studies, nicotine amide mononucleotide (NMN) (3) has been associated with properties such as anti-aging, cardio and brain protection, while animal studies are confirming its potential for lifespan extension. Recent studies of resveratrol (4) have shown its preventive effects for cardiovascular diseases and stroke, potential for lifespan extension and is associated with numerous health benefits. Healthy food supplement, containing a combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol should have stronger antioxidant effects and more positive effects on immune function and healthy blood flow compared to each product used separately, and is safe for use.
Description
Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement))
= 2 og * Discussion While positive effects of Vitamin C and red ginseng have been known for centuries, NMN and resveratrol are getting in the focus in the last years.
As this is a novel combination, below are presented effects of each of these products individually. Vitamin C (1) Vitamin C is a natural antioxidant and crucial for endothelial and organ protection. Vitamin C plays a role in mediating inflammation through antioxidant activities and is also important [0 as a cothctor/on-substrate for the synthesis of endogenous adrenaline, cortisol, and vasopressin, A growing body of evidence suggesting that vitamin C, prevents neutrophil-induced lipid oxidation ad protects against he loss of the endothelial barrier, Marked improvements in capillary fragility have also been reported with NAM and vitamin C combinations, Consumption of high-dose vitamin C (1250 mg per day) enhances functional and structural properties of serum lipoprotein to improve antioxidant, anti-atheroscleratic, and anti-aging effects via regulation of anti-inflagunatory microRNA.
Benefits of high doses of Vitamin C include attenuating oxidative stress and inflanunalion, improving vasopressor synthesis, enhancing mune cell function, improving endovascular function, and epigenetic immmmologic modifications.
2% Higher intakes of vitamin C and linoleic acid and lower intakes of fats and carbohydrates are assooiated with better skiraging appearance. Promoting healthy dietary behaviors may have additional benefit for skin appearance in addition to other health outcomes in the population.
Red Ginseng (2) Korean red ginseng has been used in traditional Chinese medicine as an overall wellness supplement for centuries, It has been used to: boost the bomune system, improve heart health, treat diabetes, increase energy, decrease stress, treat impotence. Korean FDA has approved it for use for improving inunune function and for maintaining healthy blood How.
NMN {Nicotinamide Mononueleotide) Moleenle (3) NMN naturally exists in avocadoes, tomatoes, cucumber, cabbages, broccoli, and raw beet, In the laboratory, 11 is available as nicotinamide mononucleotide bulk powder.
In the human body, NMN is the principal source of energy within the cells, As we age, cellular energy decreases due to the low levels of nicotinamide mononucleotide and subsequent reduction of NAD. Administering NMN will reverse the process and compensate for the deficit, MMN exists in both alpha (a) and beta (B) forms. However, B-NMN is the most active form. This bioactive nuclentide is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide or NAD. FDA recommends that any human being needs approximately 560 mg of NMN per day.
Human Clinical Trials with NMN - There are 113 ongoing clinical trials in humans that are investigating NAD precursors INMN, NR and Niacin}, majority of them are not completed and only few have results published. The most important study in humans was a study in Japanese man, that showed that the
- single oral administration of NMN up to 500 mg was safe and welltolerated in healthy men without causing any significant deleterious effects. it has demonstrated that the oral administration of NMN is feasible and could be a therapeutic strategy to replenish cellular NAD levels to mitigate aging-related functional disorders in humans. - Trials in humans with results are: 18 o An international collaborative team including researchers from Keio University in Tokyo and Washington University School of Medicine in St, Louis is running a Phase I human clinical study of NMN in Japan.
Clinical trials examining the safety and efficacy of NMN are also currently being run at Washington University, investigating the effect on insulin sensitivity, o endothelial function, lipids, body and liver fat and markers of cardiovascular and metabolic health.
A randomized, double-blind, three-arm crossover pharmacokinetic study in 12 human subjects showed that NR raises NAD+ by as much as 2.7-fold in human blood with a single oral dose of 1000 mg.
o endothelial function, lipids, body and liver fat and markers of cardiovascular and metabolic health.
A randomized, double-blind, three-arm crossover pharmacokinetic study in 12 human subjects showed that NR raises NAD+ by as much as 2.7-fold in human blood with a single oral dose of 1000 mg.
o Researchers at the University of Washington have completed a clinical trial! with 140 participants showing that orally administered NR gives a dose dependent increase in NAD+ from 250-1000 mg/d plateauing at a 2-fold increase in NAD+. at day nine.
Researchers have also reported positive effects of NR on vascular endothelial Function o in healthy middle-aged and older adults, with further investigations of motor and cognitive changes to come.
o Recently, researchers have found that a resveratrol analog called plerostilbene combined with NR seemed to help ALS/Lou Gehrig's patients.® o Most recently, a placebo-controlled study assessing 500 mg of NR, taken twice daily by 70- to 80-year olds, showed increases in NAD+ in blood {but not muscle.) Inflammation fell and, unexpectedly, mitochondrial activity did toa. Multiple other studies are now underway assessing the effects of NR on muscle mitochondria! function, cognition, immune function, kidney function,
o Traumatic brain injury, brown fal activity, lipid accumulation, energy metabolism, cardiovascular risk, body composition, and acetylcarnitine levels, Clinical trials results should be available in the new few years, What we can claim with certainly at this moment, based on clinical research data is that NMN is safe and well- tolerated in healthy men and that it is able to successfully replenish cellular NAD+ levels, And we know that decline in NAD levels is associated with aging.
NMN Animal Studies - Animal studies are confirming that the pharmacological activities of NMN include its role in cellular biochemical functions, cardio protection, diabetes, Alzheimer's disease, and complications associated with obesity. The recent - The recent groundbreaking discovery of anti-ageing activities of this chemical molety has added a valuable essence in the research involving this molecule, - Studies confirmed that manipulation of mitochondrial NAD levels by NMN results in metabolic changes that protect mitochondria against reactive oxygen species and excessive fragmentation, offering therapeutic approaches for pathophysiologic stress condition Resveratrol {4) Resveratrol is a nutrient found abundantly in the skin of red grapes that is known to have robust antioxidant and asti-inflammatory properties. The efficacy, safety, and pharmacokinetics of Resveratrol have been documented in over 244 clinical trials, with an additional 27 clinical trials currently ongoing.
Resveratrol has various biochemical and physiological effects such as antiinflammatory, antioxidative, antiprofiferative and chemo-preventive effects. Recent studies have shown its positive effects especially on cardiovascular diseases, cancer, type 2 diabetes and neurological disorders. Resveratrol is reported to potentially improve the therapeutic outcome in patients suffering from diabetes mellitus, obesity, colorectal cancer, breast cancer, multiple myeloma, metabolic syndrome, hypertension, Alzheimer's disease, stroke, cardiovascular diseases, kidney diseases, inflammatory diseases, and rhinopharyngitis. It was also proven that it mimics caloric restriction, which has numerous positive effects. Resveratrol is reported to be safe at doses up to 5 g/d, when used either alone or as a combination therapy.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1043755 | 2020-08-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
NL1044087A true NL1044087A (en) | 2022-04-04 |
NL1044087B1 NL1044087B1 (en) | 2022-07-08 |
Family
ID=78463853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL1044087A NL1044087B1 (en) | 2020-08-12 | 2021-07-06 | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) |
Country Status (1)
Country | Link |
---|---|
NL (1) | NL1044087B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009108999A1 (en) * | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
WO2017062311A1 (en) * | 2015-10-07 | 2017-04-13 | Huizenga Joel | Resetting biological pathways for defending against and repairing deterioration from human aging |
US20170266213A1 (en) * | 2015-03-16 | 2017-09-21 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products |
CN110237118A (en) * | 2019-06-06 | 2019-09-17 | 泓博元生命科技(深圳)有限公司 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
EP3682746A1 (en) * | 2017-09-14 | 2020-07-22 | Megumi Tanaka | Anti-aging agent and anti-aging method |
-
2021
- 2021-07-06 NL NL1044087A patent/NL1044087B1/en active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009108999A1 (en) * | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
US20170266213A1 (en) * | 2015-03-16 | 2017-09-21 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products |
WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
WO2017062311A1 (en) * | 2015-10-07 | 2017-04-13 | Huizenga Joel | Resetting biological pathways for defending against and repairing deterioration from human aging |
EP3682746A1 (en) * | 2017-09-14 | 2020-07-22 | Megumi Tanaka | Anti-aging agent and anti-aging method |
CN110237118A (en) * | 2019-06-06 | 2019-09-17 | 泓博元生命科技(深圳)有限公司 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
Also Published As
Publication number | Publication date |
---|---|
NL1044087B1 (en) | 2022-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7210459B2 (en) | Antiaging agent and antiaging method | |
Rossi et al. | The potential of β-hydroxy-β-methylbutyrate as a new strategy for the management of sarcopenia and sarcopenic obesity | |
CN112739222A (en) | Anti-aging agent and anti-aging method | |
JP2001526663A (en) | Medical uses of pyruvate | |
Gaytán Martínez et al. | Effect of Gymnema sylvestre administration on glycemic control, insulin secretion, and insulin sensitivity in patients with impaired glucose tolerance | |
Canguven et al. | Vitamin D and male erectile function: an updated review | |
NL1044087B1 (en) | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) | |
RU2366412C2 (en) | Compositions and treatment methods for hyperproliferative skin conditions | |
RU2657824C1 (en) | Method of biocorrection of premature aging of organism and skin | |
NL1044089B1 (en) | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) | |
JP2013100267A (en) | Vitamine-containing skin care composition for anti-inflammation | |
NL1044086B1 (en) | Combination of Zn, red ginseng, saw palmetto fruit extracts, nicotinamide mononucleotide (NMN) and resveratrol as a food supplement | |
NL1044088B1 (en) | Combination of Magnesium, Rhodiola Extract, Nicotinamide Mononucleotide (NMN) and Resveratrol as Healthy Functional Food (Dietary Supplement) | |
ITRM20130655A1 (en) | PRODUCT BASED ON AN ASSOCIATION OF GLUCOMANNAN AND INOSITLE | |
NL1044090B1 (en) | Combination of vitamin B6, ginseng, green tea extract, Ganoderma lucidum, black cohosh root, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement) | |
Laveriano‐Santos et al. | Unlocking the potential of olive residues for functional purposes: update on human intervention trials with health and cosmetic products | |
JP2008115163A (en) | Adiponectin production enhancer and stimulator | |
WO2011078323A1 (en) | Active oxygen production inhibitor and anti-hypertensive agent | |
MaSoUMI-ardakaNI et al. | Carnitine effects on serum and pancreas inflammatory response in diabetic rats | |
Galuzinska et al. | Research of antiulcer activity of dietary concentrate of phenolic compounds of apples on models of experimental ulcer in rats | |
Marziou et al. | Effect of a Dual Intervention with Vitamin D Supplementation and Voluntary Physical Exercise on Cardiac Remodeling and Function in a Mouse Model of Diet-Induced Type 2 Diabetes | |
CN108452229A (en) | Assist blood fat reducing preparation | |
Babilas | Nutritional diseases | |
WO2023182529A1 (en) | Pharmaceutical composition | |
CN101732366B (en) | Medicine with function of treating hypertension, hyperlipoidemia, diabetes and sleep disorder |